ADTX stock rose in morning trade after the company announced the release of its immune monitoring service on February 1, 2021.

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the operational launch of the AditxtScore™ Immune Monitoring Platform as of February 1st, 2021.

The initial application of the platform will be AditxtScore™ for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus. Infection status will be determined by evaluating the presence or absence of the virus, and immunity status by measuring levels of antibodies against viral antigens and their ability to neutralize the virus. Aditxt will soon be expanding the panel to measure other components of the immune response such as cellular immunity.

AditxtScore™ for COVID-19 will be available as a Lab Developed Test (LDT) and processed at the AditxtScore™ Immune Monitoring Center, which will operate as a CLIA-certified reference lab for the Company’s prospective channel partners, including labs and hospitals.

“Since the start of the pandemic, the focus has been on infection status. Moving forward, we believe the need for monitoring the presence and durability of immunity will continue to grow. By assessing infection status together with immunity status, AditxtScore™ for COVID-19 will be well positioned to address both needs. We’re currently in discussions with labs, hospitals and other channel partners around the world interested in incorporating AditxtScore™ into their offerings. By acting as a reference lab, prospective channel partners can rapidly deploy the service without the need for additional equipment or staffing on their part,” stated Amro Albanna, Co-founder and CEO of Aditxt.

finviz dynamic chart for  adtx

To get these stocks much faster (real-time) with alerts, check out the tool we use here. There’s nothing like it on the market.

close

Don’t miss these catalysts!

We don’t spam! Read our privacy policy for more info.